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Abstract : Nuclear particle application in cancer treatment has a long history. 
Physicists played an important role in the development of particle therapy. 
Experimentations using neutrons, protons, heavy ions and rr~ mesons for their 
therapeutic applications got initiated soon after they are made available.
In the late 30 's In Berkeley, California, work began on neutrons, the first 
particle used for cancer treatment. More than 10,000 patients have been treated 
with neutrons in about 20 centers around the world. Fast neutrons appear to be 
the treatment of choice for inoperable salivary gland tumors. The other tumor 
types or sites for which neutron therapy may benefit are slowly growing, well- 
differentiated soft tissue sarcomas, melanomas and locally extended prostatic 
adenocarcinomas.
The use of protons in radiotherapy was proposed in 1946. Biomedical 
research using protons began in Berkeley, soon after the 184" cyclotron was in 
operation, but most of the developments and clinical work took place in Uppsala 
(Sweden), Harvard (USA), USSR and Japan. More than 5000 patients have 
been treated. Protons appear to be the treatment of choice for choroidal 
melanoma, and they give impressive clinical results for the treatment of bony 
and cartilagenoijs tumors of the skull base and cervical spine. In addition, 
proton beams are successfully used for pituitary related problems and for the 
treatment of arterio-venous malformations.
The clinical results with helium ions in Berkeley are very similar to the 
proton results. Heavy ions, carbon, neon, silicon and argon are also under 
investigation in Berkeley. About 300 patients have been treated. Although no 
definitive statements can be made at this time regarding the role of heavy ions 
in radiotherapy, the results suggest that they may be of value in treating tumors 
of unusual histology located in sites close to critical structures.
The pion therapy program got started in Los Alamos in 1973 and soon after 
in Vancouver, Canada and Villigen, Switzerland. Among these three centers, 
about 1000 patients were treated. The pion therapy program in Los Alamos was 
discontinued several years ago, but the programs in Vancouver, and Villigen are 
still in progress. Pion treatment results of glioblastoma patients in Vancouver 
and nonresectablo soft tissue sarcoma patients in Villigen look promising.
The use of charged particles in radiotherapy necessitated the developments 
of precise treatment planning in three dimensions. The CT and NMR imaging 
techniques has made it possible to use these beams effectively. In addition to 
the demonstrated improvements in the treatment of certain tumors, the introduc­
tion of nuclear particles in cancer treatment accelerated the overall developments 
of treatment planning and the radiobiological understanding of acute and late 
effects in normal tissues. These developments in turn are helping conventional 
radiotherapy.
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I • Introduction
The discipline of Radiotherapy is an excellent example of a successful interdis­
ciplinary effort where physicists play an important role. Of alt modalities used
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in cancer management, radiation therapy offers the greatest probability of tumor 
control while preserving normal tissues. Radiotherapy, like surgery, is essentially 
intended to control local regional cancer. Despite the use of megavoltage X-rays 
in conventional radiotherapy, approximately 1/3 of the patients treated in the 
United States die because of failure to control the primary tumor. The rationale 
of using nuclear particles is to further improve the control of the primary tumor.
Figure 1 shows the schematic representation of target volume and treatment 
volume as practiced in radiotherapy. The use of high energy X-rays in radiotherapy 
and increasing knowledge on the nature and extension of tumor helps reduce the
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Figure I. Schematic representation target volume and treatment volume as 
practiced in radiotherapy.
treatment volume. The treatment volumes in megavoltage radiotherapy, in general, 
are much larger than the target volumes by a factor of 3 to 6 . Surgery currently 
achieves high control rates for many tumors treated at an early stage and the 
surgical treatment volumes are very close to the target volumes. The ability to 
spare the integrity and the function of normal tissues within the treatment volume 
is what makes radiotherapy preferable to surgery. The therapist gives the maximum 
dose tolerated by these normal tissues to improve the chances of tumor control. 
The tolerance of normal tissue decreases with increasing volume of the normal 
tissue in the radiation field. With the use of heavy charged particles, it is 
^ssible to reduce tha treatment volume and, hence, increase the dose to the tumor 
by 10-30'A'> without exceeding normal tissue tolerance.
2. Fractionation in radiotherapy
Early radiation therapy consisted of single treatments. While such treatments 
were found to be effective for skin cancer, they were not effective for deep seated 
tumors. As early as 1914, Schwarz suggested that fractionated treatments would be 
more effective because he felt that the mitotic cells may be more radiosensitive. 
However, the rationale for fractionation came from the famous experiments in 1927 
on the ram testicle. The skin of the testicle as a model for normal tissue and the 
sterilization of the testicle as a model for tumor sterilization were considered. 
It was shown that by fractionating the total dose, sterilization can be achieved 
with less skin damage. Another newly recognized rationale for fractionation 
could be the presence of hypoxic but viable tumor cells that are radioresistant. 
During fractionation, the hypoxic cells get reoxygenated making them radiosensi­
tive. The redistribution of tumor cells in cell cycle and reoxygenation of hypoxic 
tumor cells during fractionation sensitize tumor cells. We can say that the 
tumor cells sensitize themselves during fractionated treatments. With the introduc­
tion of megavoltage X-rays, the limiting normal tissues are generally non-prolifera­
ting and hence will not be sensitized. The introduction of particles in radiotherapy 
stimulated radiobiological investigations on acute and late effects of normal tissues 
and their modification with LET. Now it is further established that at a dose 
of ~  2Gy/fr, the late responding normal tissues are spared preferentially compared 
to acutely responding normal tissues.
3. Rationale of using nuclear particles in radiotherapy
The use of nuclear particles in radiotherapy is to further improve local tumor 
control without exceeding normal tissue tolerance.
This can, in principle, be achieved in two ways :
(i) Physical; Use of heavy charged particles with improved dose localization 
characteristics permit the deliverence of higher tumor doses without 
exceeding the normal tissue tolerance.
(ii) Radiobiological : Particles may preferentially be more effective on cancer 
cells compared to rK>rmal cells.
3.1. Dose localization characteristics of particles :
Radiations can be broadly divided into two groups : 1. exponentially attenuating
and 2. Bragg ionization characteristics with a well defined range. X-rays and fast 
neutrons belong to the first group and heavy charged particles (protons, heavy 
ions and pions) belong to the second group. Except for the initial dose build 
up for high energy X-rays and fast neutrons, the dose decreases with depth of 
penetration. For heavy charged particles, on the other hand, the dose deposited 
increases slowly with depth and then rises sharply near the end of the range 
due to a* Bragg peak effect. There is practically no dose beyond the range of
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thoDarliole. Fiqura 2 shows the depth dose distribution of protons as a tapre-
sentotive of heavy charged particles. In addition to the Bragg peak effect near
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Figure 2. Depth dose distributions of proton bucims. Ndnow peak is for 
monocnergetic beam and bioad peak is an extreme case of radiating tissue 
thought out the depth of penetration.
the end of the range, negative pions exhibit a unique phenomenon when they 
come to rest. Negative pions (being negatively charged) are captured by atomic 
nuclei in the medium, and the resulting nucleus disintegrates yielding various 
particles including some short-range and heavily ionizing fragments. In addition 
to Bragg peak effect, this phenomenon increases the dose with depth. The LET 
(dE/dx) at the pion stopping region is also increased because of heavily ionizing 
fragments. The Bragg peak of nearly monoenergetic heavy charged particles 
extracted from accelerators is quite narrow and is frequently insufficient to cover 
the treatment volumes encountered in radiotherapy. The Bragg peak can be 
broadened by introducing an absorber of variable thickness. The dose at the 
Bragg peak decreases with increasing peak width but is never lower than the 
dose at the entrance. The linear energy transfer (LE T) of heavy charged particles 
at depth, especially at the Bragg peak position, is greater than at the entrance, 
whereas for high energy gamma rays and fast neutrons, there are no significant 
differences in LET with depth of penetration.
X-rays and electrons are often referred to as low -LET radiations, but even 
these radiations deposit a small fraction of their dose at LET about 30 keV//xm. 
The high LET component extends to about 100 keV//tm for proton beams, to about 
250 keV//tm for helium ion beams, to about 900 keV/fim for pions and fast 
neutrons, and is even higher for heavy ions. The difference between high-LET
radiations is in relative proportion of does in various LET intervals and the 
maximum LET. All high-LET radiations are really mixtures of various LET'S.
The depth dose distribution of all particles is shown in Figure 3. The depth 
dose distributions of all charged particles are similar. Among the charged
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particles beams, the proton beams are the least expensive to produce and they 
havo the best dose localization advantage. Protons, however, can be considered 
as a low LET radiation.
3.2. Radiobiological characteristics of particles :
The known major radiobiological factors which affect tumor control include 
recovery from sublethal and potentially lethal damage, oxygen effect, variation of 
radiosensitivity as a function of cell cycle (cell age) and cell proliferation after 
irradiation. The RBE and OER change with LET. The RBE increases with LET 
reaching a maximum around 100 keV/#im and decreases with further increase 
in LET due to saturation at higher LET values. The OER decreases with increasing 
LET reaching unity at around 100 keV/fim (see Figure 4 ). For therapeutically 
relevant beams of particles, the typical RBE and OER values are given in Table 1. 
The repair capacity of cells reduces with increasing LET and, hence, the RBE of 
high-LET radiations increases with decreasing dose per fraction.
The higher RBE values, by themselves, are of no advantage in radiotherapy 
unless these values are higher than the RBE values of limiting normal tissues. 
The RBE of neutrons was found to depend on growth rate of the tumors. The 
slower the tumor growth rate, the higher the RBE. An RBE value of nearly a 
2
factor of two greater than normal tissues was found for well differentiated lung 
metastasis from salivary gland tumors.
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Figure 4. Variation of RBE and OER plotted as a function of LET ( d E / d x ) .
1. RBE for cell killing at higher survival level.
2. RBE for cell killing at lower survival level.
3. OER.
Table 1. RBE and OER of particles.
Radiation RBE OER
X 1 3
P 1.1 3
He 1.3 2.8
If' 1.6 2.5
C 2 2.5
Ne 2.5 2
Ar 3 1.8
n 3 1.8
3.3. Fast neutrons theropy ;
The first fast neutron therapy clinical trial was performed at Berkeley California 
during December 1939-February 1943, a period long before the advent of mega­
voltage radiotherapy and radiobiological techniques. Tw o hundred and twenty 
six patients with advanced tumors treated. After this trial, it was concluded 
"neutron therapy as administered by us had resulted in such bad late sequela 
in proporation to the few good results that it should not be continued". Reduction 
of the oxygen effect by fast neutrons was unknown at the time of these clinical 
studies. However, radiobiological experiments showed enhancement effect on 
tumcHS compared to normal tissues. In the light of radiobiological knowledge 
regarding the oxygen effect in radiotherapy and the reduction in OER for fast
neutrons, in Great Britain the need was felt to reinvestigate their use in radio­
therapy. After a careful study of fast neutron effects on normal tissues and tumors, 
patient treatments were started at the Hammersmith Hospital, London, in 1967. 
After the initial encouraging results, a randomized clinical trial, to compare the 
clinical results of fast neutrons with megavoltage X or gamma rays, was started 
in 1971. Neutron treatments were given 3 days per week for four weeks. A  total 
dose of 1560 rad of neutrons was given in 12 equal fractions. The tumor 
regression, relief of pain and ulceration after neutron treatment were found to be 
significantly better than photon treatments. The details of neutron therapy 
techniques are extensively discussed in a book by Catterell and Bewley (1979). 
These encouraging results from Hummersmith Hospital stimulated great interest 
around the world in the application of fast neutrons and other nuclear particles in 
radiotherapy.
A  list of neutron therapy centers and the number of patients treated is presented 
in Table 2. Some of these centers are medically dedicated facilities with isocentric 
beam delivery capabilities to overcome some of the problems encountered with fixed
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Table 2. Neutron therapy facilities.
Facili­
ties Country
Patients
treated
Future
facilities
15 USA 10,000 Super
U K
Netherlands
(discontinued)
Germany
France
Belgium
Japan
Korea
Saudi Arabia 
South Africa 
India
Conducting
Cyclotrons
(USA)
horizontal neutron beams. More than 10,000 patients have been treated with 
neutron beams in about 15 centers around the world- Fast neutrons appear to be 
the treatment of choice for inoperable salivary gland tumors. The other tumor 
types or sites for which neutron therapy may benefit are slowly growing, well 
differentiated soft tissue sarcomas, melanomas, and locally extended prostate 
adenocarcinomas. No definitive advantage for neutrons has been demonstrated so 
far in treating tumors of CNS, lung, pancreas bladder and cervix.
3.4. Proton therapy :
The potential application of protons and other heavy charged particles was proposed 
in 1946. The first clinical application of proton beams was conducted in Berkeley
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in early 50's at the "184”  cyclotron. Subsequently, the cyclotron was modified 
to further increase the energy making proton beams unsuitable for radiotherapy. 
However, the work was carried out using helium ion beams. Clinical work with 
protons has been ongoing in Sweden since 1956 and at Harvard since 1961, and 
in the Soviet Union since 1965, The Uppsala cyclotron is currently being modified 
and the patient treatments are expected soon. Most of the proton work in the U S A  
was done using the Harvard Cyclotron. Radiobiologically, protons can be 
considered as a low LET radiation making it easier to apply the conventional radio­
therapy experience to proton radiotherapy. Because of the Bragg peak effect and 
its sharply defined range, protons offer the potential to confine the high dose region 
precisely to the tumor volume and to minimize the dose to the surrounding normal 
tissue. The dose to the normal tissues outside the target volume was about 70% of 
the tumor dose using|]';“Co gamma rays to about 22 ;. using protons (see Figure 5 ),
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effect of megavoltage X-rays to all normal tissues in the beam oath r
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The early work with protons was mainly confined to treating human diseases 
associated with the pituitary gland. Large field radiotherapy has been carried out
Table 3. Proton therapy facilities.
CountriesNumber of facilities
Patients
treated
7000Current (8) USA
Sweden
U SSR
Switzerland
Japan
Under
Construction (9)
Planned (5 )
in Uppsala since 1956 and in the Soviet Union in 1960's. The interest in fast 
neutron, pion and heavy ions (in radiotherapy) rejuvenated interest in protons and 
helium ions (since early 1970's) for large field radiotherapy using conventional 
fractionation. The ability to manipulate the dose in depth dimensions with heavy 
charged particles and the availibility of C T scanners helped develop three 
dimensional treatment planning techniques. These developments helped bring 
treatment volumes closer to target volumes which permitted the delivery of 
10-30 higher doses to the treatment volume without exceeding normal tissue 
tolerance.
Proton beams are the treatment of choice for choroidal melanoma for which the 
treatment earlier was mainly enucleation. Proton beams are also found to give 
impressive results for the treatment of chordoma and chondrosarcoma of the skull 
base and cervical spine (local control and disease free survival are 77,..).
With the routine use of C T  scanners, the detection of arteriovenous malforma­
tions (A -V ) has been increasing. The proton beams were found to be very effective 
in (A -V ) treatment. This success accelerated the development in using narrow 
photon beams of megavoltage X-rays and gamma using multiple “ "Co gamma rays. 
The experience of helium ion beams is consistent with the proton beams.
The first medically dedicated proton accelerator is installed at Loma Linda 
University in California.
3.5. Heavy Io n s :
Tw o accelerators, a low energy heavy ion linear accelerator and a high energy 
proton accelerator, (Bevatron), located nearby at Lawrence Berkeley Laboratory, 
were connected with a beam line in 1974. With some modifications in both 
accelerators, heavy ions such as C , Ne and Ar were accelerated with adequate 
intensity and range for radiotherapeutic application. This combined facility Is 
known as BEVALAC. It is interesting to note that the radiotherapy interest of
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heavy ions helped get the heavy ion physics research started. Heavy ion facilities 
are currently being built in Germany and Japan.
The dose localization characteristics of heavy ions are similar but slightly 
inferior to proton and helium ions. The LET of these beams, especially in the peak 
region, is much higher and increases from the proximal to the distal region of the 
modified Bragg peak. Since these changes in LET introduce changes in RBE across 
the treatment area, the dose across the peak is varied to produce uniform biological 
effect. The techniques of shaping dose distributions to get uniform biological 
effect were developed for various heavy ions such as C, Ne and Ar and clinically 
relevant RBE values were determined. The tumors that are found to respond well 
for fast neutrons can, in principle, be treated better with heavy ions because of 
their good dose localization characteristics. About 300 patients were treated 
with heavy ions which led to randomized trials for lung, prostate, salivary gland, 
nasopharynx, soft tissue sarcoma and glioblastoma tumor sites.
3.6. Negative pions :
Application of pion beams for radiotherapy were proposed in 1961. Pion beams 
of intensities suitable for radiotherapy became available only in the 1970’s.
Three pion beam facilities built mainly for physics research, but with adequate 
facilities for therapy, are located at Los Alamos, USA, Vancouver, Canada, and 
Villigen, Switzerland. The Swiss facility incorporates a |pion collection device 
developed at Stanford University. This device permits simultaneous multiport 
irradiation of the tumor volume.
A  total of nearly 1000 patients have been treated among the three facilities and 
the optimal doses for treating patients were developed. The program in Los Alamos 
was discontinued in the early 80's, but the programs in Canada and Switzerland 
are active. The Canadian group reported encouraging results in treating glioblas­
toma using a randomized trial. The Swiss group reported encouraging results in 
treating non-resectable soft tissue sarcomas.
4. Conclusion
Particle therapy programs gave an impetus for further developments in radiation 
physics as well as in radiation biology. These programs also helped to attract 
many talented high energy physicists that contributed developments of three 
dimensional treatment planning which, in turn, is helping to improve conventional 
radiotherapy. Particle therapy also is paving the way towards individualized 
radiotherapy treatments. The impact of particle therapy, so far, has been in the 
treatment of relatively rare tumors.
Methods should be developed to identify tumors that have a better progtK>sis
® taken before treatment. The pitfall of the 
particle radiotherapy, in general, has been that the expectations were too high and
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it is quite possible that further improvements in radiotherapy may become apparent 
in less spectacular ways. Finding optimum doses of high-LET particles that need 
to be used to be minimize recurrences and still be within acceptable tolerance 
limits of normal tissues turned out to be more complicated than expected.
A  well-coordinated, international effort is needed to assess the potential for 
heavy particles in therapy. Such an effort between Europe and the USA is in 
progress and the extension of this coordination to other countries is being sought 
since it takes a large patient pool to conduct various therapeutic trials.
Evaluation of a new method and the presentation of convincing clinical 
evidence requires ten years or longer; hence progress is very slow and comes in 
small steps.
The use of nuclear particles in cancer treatment provides an excellent 
opportunity for interdisciplinary research involving physicists, engineers and 
biomedical scientists to develop new techniques for tumor diagnosis, localization, 
and treatment planning.
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